Molecular mediators of hepatic steatosis and liver injury.
Molecular mediators of hepatic steatosis and liver injury.
复制标题
DOI：
10.1172/jci22422
复制
发表时间：
2004-07
期刊：
影响因子：
--
通讯作者：
J. Browning;J. Horton
中科院分区：
文献类型：
--
作者：
J. Browning;J. Horton
肥胖及其相关的合并症是21世纪医学界面临的最普遍和最具挑战性的疾病之一。肥胖的一个主要代谢后果是胰岛素抵抗，这与肝脏中甘油三酯的沉积密切相关。肝脏脂肪变性可能是一种良性的非炎症性疾病，似乎没有不良后遗症，也可能与脂肪性肝炎有关：这种疾病可能导致终末期肝病，占美国肝脏移植的14%。在这里，我们强调了最近的进展，我们的理解的分子事件，有助于肝脂肪变性和非酒精性脂肪性肝炎。
Obesity and its associated comorbidities are among the most prevalent and challenging conditions confronting the medical profession in the 21st century. A major metabolic consequence of obesity is insulin resistance, which is strongly associated with the deposition of triglycerides in the liver. Hepatic steatosis can either be a benign, noninflammatory condition that appears to have no adverse sequelae or can be associated with steatohepatitis: a condition that can result in end-stage liver disease, accounting for up to 14% of liver transplants in the US. Here we highlight recent advances in our understanding of the molecular events contributing to hepatic steatosis and nonalcoholic steatohepatitis.